Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

GeneDx Holdings (WGS) EPS (Weighted Average and Diluted): 2019-2024

Historic EPS (Weighted Average and Diluted) for GeneDx Holdings (WGS) over the last 6 years, with Dec 2024 value amounting to -$1.94.

  • GeneDx Holdings' EPS (Weighted Average and Diluted) rose 12.90% to -$0.27 in Q3 2025 from the same period last year, while for Sep 2025 it was $0.09, marking a year-over-year increase of 102.89%. This contributed to the annual value of -$1.94 for FY2024, which is 73.17% up from last year.
  • Per GeneDx Holdings' latest filing, its EPS (Weighted Average and Diluted) stood at -$1.94 for FY2024, which was up 73.17% from -$7.23 recorded in FY2023.
  • GeneDx Holdings' 5-year EPS (Weighted Average and Diluted) high stood at -$1.94 for FY2024, and its period low was -$47,036 during FY2020.
  • Its 3-year average for EPS (Weighted Average and Diluted) is -$20.93, with a median of -$7.23 in 2023.
  • Its EPS (Weighted Average and Diluted) has fluctuated over the past 5 years, first skyrocketed by 100.00% in 2021, then crashed by 2,262.56% in 2022.
  • Over the past 5 years, GeneDx Holdings' EPS (Weighted Average and Diluted) (Yearly) stood at -$47,036 in 2020, then skyrocketed by 100.00% to -$2.27 in 2021, then slumped by 2,262.56% to -$53.63 in 2022, then spiked by 86.52% to -$7.23 in 2023, then spiked by 73.17% to -$1.94 in 2024.